jcm-logo

Journal Browser

Journal Browser

Transcatheter Aortic Valve Implantation: Recent Advances and Future Directions

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 794

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Cardiology, Rabin Medical Center, Petach Tikva 4941492, Israel
2. Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
Interests: echocardiography; valvular heart disease; structural heart interventions; transcatheter edge-to-edge repair; transcatheter aortic valve implantation

E-Mail Website
Guest Editor
1. Department of Cardiology, Rabin Medical Center, Petach-Tikva 4941492, Israel
2. Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel
Interests: interventional cardiology; valvular heart disease; transcatheter edge-to-edge repair; transcatheter aortic valve implantation

Special Issue Information

Dear Colleagues,

Since its introduction in 2002, transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with aortic valve disorders. Paralleling improvements in device design and delivery, operator experience, imaging guidance, supportive treatment, and risk stratification, the procedure has gradually assumed a central therapeutic role across a wide range of clinical scenarios and patient profiles. In this Special Issue of the Journal of Clinical Medicine, we aim to provide readers with an updated overview of the diagnostic, prognostic, and technical aspects related to TAVI, and further highlight remaining challenges and future directions in this breakthrough intervention. Both original research and review articles dealing with any of these topics are most welcome.

Dr. Alon Shechter
Dr. Pablo Codner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transcatheter aortic valve implantation
  • transcatheter aortic valve replacement
  • aortic valve stenosis
  • aortic valve regurgitation
  • aoric valve disease
  • cardiac imaging
  • artifical intelligence
  • machine learning

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 1398 KiB  
Article
Predicting the Burden for Surgical Aortic Valve Replacement in a Tertiary Centre: The Impact of Aged Populations for the Next Decades
by Rafael Maniés Pereira, Nuno Guerra, João Moreira Gonçalves, Ricardo Ferreira, Ângelo Nobre, Dulce Brito, Teresa Ferreira Rodrigues and Tiago R. Velho
J. Clin. Med. 2025, 14(10), 3365; https://doi.org/10.3390/jcm14103365 - 12 May 2025
Viewed by 214
Abstract
Background/Objectives: The incidence of aortic stenosis (AS) is predicted to rise with the aging population, emerging as a growing public health challenge in developed countries, leading to an increased demand for intervention. Our aim is to predict the evolution of proposed cases for [...] Read more.
Background/Objectives: The incidence of aortic stenosis (AS) is predicted to rise with the aging population, emerging as a growing public health challenge in developed countries, leading to an increased demand for intervention. Our aim is to predict the evolution of proposed cases for SAVR in the geographic referral area of our tertiary hospital until 2041. Methods: We used data from the Portuguese Census for 2001, 2011, and 2021 to analyze the resident population within the Cardiothoracic Surgery Department’s referral area. Applying population projection methods (rate of geometric growth), we projected demographic trends over 20 years, from 2021 to 2041. Our analysis focused on AS cases who underwent SAVR in our department between 2001–2011 and 2011–2021. Results: Between 2001 and 2021, there was an increase in the overall population, particularly among the elderly (1.4% growth rate in the population ≥ 65 years old). The aging index increased from 128.4 (110.5–180.6) in 2001 to 189.1 (155.9–222.5) in 2021 (p-value < 0.001). Similarly, the longevity index significantly increased between 2001 [42.6 (40.8–44.80)] and 2021 [49.30 (47.7–51.8)] (p-value < 0.001). The number of SAVRs performed increased, with a mean increase of 8.11 surgeries/year (R2 = 0.6457, p < 0.001). By 2041, our referral center will increase SAVR by at least 51 surgeries/year in a decreasing growth rate scenario, and 67 surgeries/year in a growth rate stagnation scenario. Conclusions: The ongoing trend of population aging will increase the demand for healthcare resources, particularly within the cardiovascular domain. Accurately assessing the volume of SAVR is imperative for reformulating strategies to address the increasing demand effectively. Full article
Show Figures

Figure 1

Other

Jump to: Research

13 pages, 6215 KiB  
Systematic Review
Peri-Procedural Continuation Versus Interruption of Anticoagulation for Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis
by Jacinthe Khater, Marco Frazzetto, Filippo Luca Gurgoglione, Jasim Hasan, Davide Donelli, Guilherme Attizzani and Bernardo Cortese
J. Clin. Med. 2025, 14(10), 3563; https://doi.org/10.3390/jcm14103563 - 20 May 2025
Viewed by 143
Abstract
Background/Objectives: Oral anticoagulation therapy (OAC) is crucial for reducing the risk of ischemic complications in patients with atrial fibrillation (AF). However, OAC also increases the risk of major bleeding events. The optimal management of OAC in patients with AF undergoing transaortic valve [...] Read more.
Background/Objectives: Oral anticoagulation therapy (OAC) is crucial for reducing the risk of ischemic complications in patients with atrial fibrillation (AF). However, OAC also increases the risk of major bleeding events. The optimal management of OAC in patients with AF undergoing transaortic valve implantation (TAVI) is unclear. This study aimed to compare the efficacy and safety of OAC interruption vs. continuation in patients with AF scheduled for TAVI. Methods: PubMed, EMBASE, and Cochrane were searched to include all pertinent randomized and observational studies. The primary endpoint was the occurrence of net adverse clinical events (NACE), a composite of all-cause death, major vascular complications, and major bleeding at 30-day follow-up. Secondary endpoints included all-cause death, cardiovascular death, major vascular complications, major bleeding, any bleeding, stroke, non-fatal myocardial infarction, and the need for red-packed blood transfusion. Results: A total of three studies and 2773 patients were included in the analysis (1314 were allocated to continuation of OAC therapy and 1459 to interruption of OAC therapy during TAVI). The two study groups experienced a similar rate of NACE (OR = 0.89 [95% CI 0.61 to 1.31], I2 = 77%, p = 0.56) compared to the OAC-interruption group. No significant differences were observed in the rate of all-cause death (p = 0.21), cardiovascular death (p = 0.35), major vascular complications (p = 0.84), major bleeding events (p = 0.47), total bleeding events (p = 0.62), or non-fatal MI (p = 0.55). Interestingly, the OAC-continuation group experienced a lower occurrence of stroke (OR = 0.62 [95% CI 0.39 to 0.97], I2 = 0%, p = 0.04) and the need for red packed blood cells (OR = 0.66 [95% CI 0.50 to 0.86], I2 = 20%, p < 0.01) compared to the OAC-interruption group. Conclusions: In patients with AF undergoing TAVI, there was no significant difference between interruption and continuation of OAC in terms of NACE, composite of all-cause death, major vascular complications, or major bleeding at 30-day follow-up. Of interest, the OAC-continuation group patients experienced lower rates of stroke and the need for blood transfusion. Full article
Show Figures

Figure 1

Back to TopTop